O Shaughnessy Asset Management LLC Sells 895 Shares of Edwards Lifesciences Co. (NYSE:EW)

O Shaughnessy Asset Management LLC reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 3.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,164 shares of the medical research company’s stock after selling 895 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Edwards Lifesciences were worth $1,789,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Abacus Planning Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares in the last quarter. Bowman & Co S.C. boosted its stake in Edwards Lifesciences by 1.2% during the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after acquiring an additional 148 shares in the last quarter. Moors & Cabot Inc. grew its holdings in Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock worth $4,041,000 after purchasing an additional 152 shares during the period. Pegasus Asset Management Inc. increased its stake in shares of Edwards Lifesciences by 0.4% during the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after purchasing an additional 159 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 1.9% during the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock valued at $634,000 after purchasing an additional 162 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 4.9 %

NYSE:EW opened at $69.39 on Friday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The business has a fifty day moving average price of $71.74 and a 200-day moving average price of $70.62. The firm has a market capitalization of $40.79 billion, a price-to-earnings ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on EW. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $79.95.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now owns 30,387 shares of the company’s stock, valued at $2,153,526.69. This represents a 27.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,189,770.56. This trade represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,553 shares of company stock worth $4,513,064 over the last three months. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.